Stocks · News reference

EXCLUSIVE: Sunshine Biopharma Receives Canadian Approval for Generic Enalapril for Hypertension in Four Dosage Strengths; Shipping To begin By Year-End 2026

Aug 19, 2026, 12:30 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 26, 2026, 1:03 PMBenzinga Newsdesk
Sunshine Biopharma Announces Updates On Its K1.1 mRNA Tumor Suppressor; Outlines Plans For Program
Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company offering and researching life-saving medicines across multiple therapeutic areas including oncology and antivirals, today
Read original at benzinga
SBFM
BenzingaAug 26, 2026, 12:31 PMVandana Singh
EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer
Sunshine Biopharma outlines K1.1 mRNA pipeline updates, advancing dual oncology therapy to target cold tumors in liver and lung cancer.
Read original at benzinga
MRK MRNA SBFM
BenzingaAug 26, 2026, 12:30 PMBenzinga Newsdesk
EXCLUSIVE: Sunshine Biopharma Reports Preclinical Tumor Suppression with K1.1 mRNA in Liver Cancer; Advances mRNA-Cancer Vaccine for Difficult-to-Treat Lung Cancer
Read original at benzinga
SBFM
BenzingaAug 19, 2026, 1:02 PMBenzinga Newsdesk
Sunshine Biopharma Announces Approval Of Generic Enalapril Tablets 2.5mg, 5mg, 10mg And 20mg For Canadian Market
Global anti-hypertensive drug market projected to reach $37.24 billion by 2034Enalapril is a widely prescribed ACE inhibitor used to treat hypertension, heart failure and left ventricular dysfunctionSunshine Biopharma
Read original at benzinga
SBFM